Top Markets
Coin of the day
AlloVir, Inc. AlloVir, Inc.

AlloVir, Inc.

ALVR
Rank in Stocks #25520
AlloVir, Inc. is a biotechnology company in the clinical stage, dedicated to... AlloVir, Inc. is a biotechnology company in the clinical stage, dedicated to researching and developing allogeneic, "off-the-shelf" multi-virus specific T-cell (VST) therapies. Its primary goal is to prevent and treat severe diseases caused by viral infections. The company's lead product, posoleucel, is an allogeneic, ready-to-use VST therapy designed to combat several significant viruses, including BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Beyond this flagship candidate, AlloVir's pipeline features additional investigational treatments in various stages of development. These include ALVR106, which targets respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109, developed to address SARS-CoV-2 and COVID-19; ALVR107, for treating hepatitis B; and ALVR108. Established in 2013, the company was initially known as ViraCyte, Inc. before officially rebranding as AlloVir, Inc. in May 2019. Its headquarters are located in Waltham, Massachusetts.
Share Price
$9.81
Last synced: 2025-03-18
Market Cap
$48.68M
Change (1 day)
1.55%
Change (1 year)
0.00%
Country
US
Trade AlloVir, Inc. (ALVR)

Category

Dividend yield history for AlloVir, Inc. (ALVR)
AlloVir, Inc. (stock symbol: ALVR) dividend yield (TTM) as of 2023-12-31: 0.00%
Average dividend yield, last 5 years : 0.00%
Dividend yield history for AlloVir, Inc. (ALVR) from 2022 to 2026
Dividend Yield at the end of each year (TTM)
Year Dividend Yield Change
2026 (TTM) 0.00% 0.00%
2024 0.00% 0.00%
2023 0.00% 0.00%
2022 0.00% 0.00%
Dividend yields (TTM) for similar companies or competitors
Company Dividend Yield Country
0.00%
US
0.00%
NL
3.12%
AU
0.00%
CH
0.00%
US